Barr To Pursue Generic Version of Neupogen Under Agreement With Pliva

Barr agreement with Pliva marks the generic drug marketer's second move into generic biologics, with the company aiming to become an early leader in the field. Barr will be responsible for regulatory work to establish a pathway for approval of G-CSF.